Study to check the efficacy and safety of Excimer light and Tofacitinib with Excimer light with Vaseline alba in localized vitiligo
- Conditions
- Health Condition 1: L80- Vitiligo
- Registration Number
- CTRI/2024/02/062418
- Lead Sponsor
- Dr Imran Majid
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Participants of age group 12 to 70 years to be included.
Patients with a confirmed diagnosis of vitiligo for any duration, Bilaterally symmetrical lesions of vitiligo present on any part of the body, Involving less than 5% of Body Surface area, Patients eligible for Excimer light therapy for vitiligo, Washout period of 1 week in case of topical therapy for Vitiligo and 1 month
washout period for Systemic therapy for vitiligo before enrolment, Written informed consent signed by the patient or legally acceptable
representative(s) in line with applicable regulation of country, Planned treatment in line with the Summary of Product Characteristics
any contraindication to any of the topical medications &/or Excimer therapy, women of childbearing age, pregnancy, lactation, hypersensitivity to any of the topical agents, unwillingness to conform to study protocol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the repigmenting efficacy of a combination of Excimer light with topical Tofacitinib versus Excimer light with placebo in vitiligoTimepoint: 1 year
- Secondary Outcome Measures
Name Time Method To obtain safety information in terms of adverse events on the use Excimer light <br/ ><br>with topical Tofacitinib versus Excimer light with placebo in vitiligoTimepoint: 1 year